Codiak Biosciences Inc

NASDAQ:CDAK   3:59:34 PM EDT
9.50
-0.25 (-2.56%)
Products, Regulatory

Codiak Initiates Patient Dosing In Phase 1/2 Clinical Trial Of Exosting For The Treatment Of Solid Tumors

Published: 10/01/2020 11:55 GMT
(CDAK) - Codiak Initiates Patient Dosing in Phase 1/2 Clinical Trial of Exosting™ for the Treatment of Solid Tumors.
Codiak Biosciences Inc - Safety, Biomarker and Preliminary Efficacy Data From Dose-escalation Phase of Exosting Trial is Expected in Mid-2021.
Codiak Biosciences - Intends to Enroll Further Expansion Cohorts of Patients at Optimal Exosting Dose to Be Identified in Phase 1 Portion of Clinical Program.